News & Updates

Treatment with either labetalol or nifedipine is similarly effective in reducing adverse maternal outcomes among women with mild chronic hypertension (CHTN) in pregnancy, according to a study presented at SMFM 2023.

Pregnant women may do well to avoid cannabis, with cannabis use in early pregnancy leading to adverse pregnancy outcomes, as reported in a study presented at Society for Maternal-Fetal Medicine (SMFM) 43rd Annual Pregnancy Meeting.

Pregnant women living with HIV are more likely to achieve viral suppression when treated with dual-nucleoside reverse transcriptase inhibitors (NRTI) in combination with integrase (INSTI) inhibitors compared to protease (PI) inhibitors at delivery, suggests a recent study presented at the 43rd Annual Pregnancy Meeting of the Society for Maternal Fetal Medicine (SMFM 2023).

Discontinuing oxytocin during the active stage of labour appears safe, according to the STOPOXY trial presented at SMFM 2023.

New drug applications approved by US FDA as of 01-15 February 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Uncontrolled postpartum haemorrhage (PPH) is a life-threatening complication of childbirth that is temporarily managed with uterine balloon tamponade. At SMFM 2023, researchers from the US presented findings for a new device that could control PPH safely and effectively in just 5 minutes.

Treatment with a single oral dose of azithromycin, given to women in labour who were planning a vaginal birth, significantly reduced the risk of maternal death or sepsis, according to the A-PLUS* trial presented at SMFM 2023.